Augmented Intelligence Company PercayAI Partners with Canopy Biosciences to Accelerate Drug Development

Canopy Biosciences, a leading provider of gene editing and gene expression products and services, to offer new service utilizing PercayAI’s first commercial product, CompBioTM

PercayAI, a newly launched augmented intelligence software company that helps researchers develop new drugs more quickly and successfully, has announced its first strategic, commercial partnership with Canopy Biosciences.

Canopy Biosciences, a multi-omics service provider supporting leading labs at universities, biotechnology and pharmaceutical companies around the world, will offer PercayAI’s CompBio coupled to their RNAseq and NanoString service. CompBio is software that quickly interprets data using a unique combination of artificial intelligence and contextual language processing to mimic the thought processes of biological science experts.

CompBio will complement Canopy Biosciences existing multi-omics platform and gene expression offerings by rapidly identifying non-obvious relationships within complex biological data sets. CompBio provides data in an intuitive, interactive 3D format that allows researchers to easily view all the information specific to their biological paradigm, helping scientists to have a greater understanding of the biology driving their research.

“With CompBio, researchers can explore the biological landscape and rapidly uncover insights in ways not possible with other tools,” said Preston Keller, Ph.D., Director and Chief Commercial Officer of PercayAI. “Through our partnership with Canopy Biosciences, scientists will now have access to a powerful and innovative technological service that will help to improve the speed, cost and success rate of diagnostic and drug development.”

“Canopy Biosciences licenses and provides the most ground-breaking technologies for researchers around the globe to advance the drug development process,” said Edward Weinstein, Ph.D., CEO of Canopy Biosciences. “Our collaboration with PercayAI will create a powerful union of genomics expertise with cutting-edge analysis solutions to best support scientists in drug development and lead to better patient outcomes.”

Mentioned in this Article

Stories published by EQ Staff indicate that the article has been produced by multiple authors or adapted from a press release that's been sent to the editorial team. If you'd like to submit a press release for consideration or please join the EQ Accelerate program. Feel free to drop us a line to learn more. Press releases are not guaranteed paid for placements and are selected for publishing on a merit basis.